Subtype
Urinary Tract Neoplasm
CI-CAN-00001627Explore in graph →
Non-malignant558 active trials14 approved drugs29 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001627Explore in graph →
Clinical trials
2,187 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07614594 | Non-invasive Urinary Genomics-Based Risk Assessment for Early Urothelial Carcinoma Diagnosis | recruiting | — | 800 | Henan Provincial People's HospitalOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06111235 | A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT | active not recruiting | Phase 3 | 367 | CG Oncology, Inc.INDUSTRY | 2 | Jul 1, 2026 | clinicaltrials |
| NCT06101290 | Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)(LAYOVER) | recruiting | N/A | 150 | University of California, DavisOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07119996 | Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients | recruiting | Phase 1 | 12 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07675057 | Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors | available | — | — | Eli Lilly and CompanyINDUSTRY | 0 | Jun 30, 2026 | clinicaltrials |
| NCT02012699 | Integrated Cancer Repository for Cancer Research(iCaRe2) | recruiting | — | 999,999 | University of NebraskaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05520099 | Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)(ELEPHAS-02) | active not recruiting | — | 416 | ElephasINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06940648 | Virtuoso Improving Anatomic Bladder Lesion Excision (VIABLE) Trial | enrolling by invitation | N/A | 30 | Virtuoso Surgical, Inc.INDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07327489 | Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)(ELEPHAS-05) | recruiting | — | 2,000 | ElephasINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07673016 | Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer(INSITE) | recruiting | — | 2,500 | Convergent Genomics, Inc.NETWORK | 2 | Jun 29, 2026 | clinicaltrials |
| NCT05312671 | Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer | recruiting | Phase 2 | 63 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07321210 | Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma (T-LND UTUC)(UTLUND) | recruiting | N/A | 150 | Tianjin Medical University Second HospitalOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07663747 | Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC(FIDELIO) | not yet recruiting | Phase 2 | 56 | The Netherlands Cancer InstituteOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT00942331 | Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer | completed | Phase 3 | 506 | National Cancer Institute (NCI)NIH | 2 | Jun 24, 2026 | clinicaltrials |
| NCT04018053 | 18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy | completed | Early Phase 1 | 16 | Brigham and Women's HospitalOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07664397 | Imaging Study of [89Zr]DFO-YS5 for Cancer Detection | not yet recruiting | Phase 1 | 40 | Robert Flavell, MD, PhDOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT03872947 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 138 | Toray Industries, IncINDUSTRY | 2 | Jun 23, 2026 | clinicaltrials |
| NCT04919512 | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder(SunRISe-4) | completed | Phase 2 | 163 | Janssen Research & Development, LLCINDUSTRY | 10 | Jun 23, 2026 | clinicaltrials |
| NCT06243510 | Comparison of Apixaban Versus Enoxaparin(CARE) | completed | N/A | 126 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07662863 | Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01)(SPARE-UC-01) | not yet recruiting | Phase 2 | 75 | Fudan UniversityOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03967977 | Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma | active not recruiting | Phase 3 | 420 | BeiGeneINDUSTRY | 2 | Jun 22, 2026 | clinicaltrials |
| NCT02885974 | Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer(BLAST) | completed | Phase 1 | 22 | Baylor College of MedicineOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT03768570 | Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer | active not recruiting | Phase 2 | 82 | Canadian Cancer Trials GroupNETWORK | 3 | Jun 18, 2026 | clinicaltrials |
| NCT06257264 | A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors | active not recruiting | Phase 1 | 103 | BeiGeneINDUSTRY | 6 | Jun 18, 2026 | clinicaltrials |
| NCT07484022 | Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer | recruiting | Phase 1 | 37 | Generate BiomedicinesINDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07657299 | Predictive Value of E-cadherin, β-catenin and SOX4 in Recurrence and/or Progression of Non-muscle Invasive Urinary Bladder Transitional Cell Carcinoma. A Retrospective Study | completed | — | 30 | Ain Shams UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT03677544 | Predictive Factorsfor Final Pathologic Ureteral Sections(CYSTECTOMEN) | completed | — | 748 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04944550 | New Models for the Evaluation of Preclinical Treatment for Urothelial Carcinomas of the Upper Excretory Tract.(CICLOP) | completed | — | 20 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07643415 | Spinal Versus General Anesthesia in Open Simple Prostatectomy | recruiting | N/A | 80 | Hitit UniversityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05204186 | Impact of COMORBIDities After Radical Cystectomy Using a Predictive Method With Artificial Intelligence(COMORBID-AI) | recruiting | — | 500 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06434350 | Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE) | recruiting | Phase 1 / Phase 2 | 41 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06967961 | Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers(DP-PAN-CANCER) | recruiting | N/A | 450 | Institut Claudius RegaudOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT00756639 | Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium | active not recruiting | Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05092958 | Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study | active not recruiting | Phase 3 | 654 | National Cancer Institute (NCI)NIH | 2 | Jun 12, 2026 | clinicaltrials |
| NCT06087016 | Urinary Markers by SpectrosCopy: Diagnostic Aid in oncologY - Application to Urological Cancers(MUSCADE) | completed | — | 899 | CHU de ReimsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06630416 | Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors | recruiting | Phase 2 | 64 | Northwestern UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07646145 | Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer | recruiting | Phase 2 | 30 | Shanxi Province Cancer HospitalOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03375307 | Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes | active not recruiting | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04106115 | DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr(DURANCE) | recruiting | Phase 1 / Phase 2 | 52 | University College, LondonOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07029256 | Ultrasound-Guided Core Needle Biopsy to Stage Urothelial Carcinoma of the Bladder (US UCB) | recruiting | — | 100 | Mayo ClinicOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07048457 | Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma(CONSOLIdATE-1) | recruiting | Phase 2 | 32 | Yale UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07639983 | Multi-Omics-Based Phase Ⅱ Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in HER2-Positive Muscle-Invasive Urothelial Carcinoma | not yet recruiting | Phase 2 | 44 | Sheng TaiOTHER | 0 | Jun 10, 2026 | clinicaltrials |
| NCT02717156 | Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors | active not recruiting | Phase 2 | 70 | University of Southern CaliforniaOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07524426 | Local Radiotherapy for Urinary Bladder Cancer in Patients Not Eligible for Curative Treatment(LORUP) | recruiting | N/A | 248 | Umeå UniversityOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07636772 | A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma | not yet recruiting | Phase 2 | 132 | AkesoINDUSTRY | 1 | Jun 9, 2026 | clinicaltrials |
| NCT03289962 | A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | completed | Phase 1 | 273 | Genentech, Inc.INDUSTRY | 8 | Jun 8, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 2, 2026source: clinicaltrials